Visão geral da empresa
A clinical-stage biotechnology entity, Larimar Therapeutics, Inc. is dedicated to the development of therapeutic interventions for rare diseases, leveraging a proprietary novel cell penetrating peptide technology platform. This organization operates within the broader healthcare sector, specifically functioning in the specialized biotechnology industry where research and development capital intensity is high. The company maintains a market capitalization of $528.76M and employs a workforce of 71 individuals, though specific annual revenue data is not disclosed in current filings. These financial parameters indicate that Larimar is a mid-cap enterprise with a limited revenue footprint relative to its valuation, suggesting that its market value is primarily derived from its intellectual property pipeline and future potential rather than current operational cash generation.
Saúde financeira
The company reports a net income of $-165,672,992 and an EBITDA of $-172,147,008 for the trailing twelve months, while revenue figures are not available. The substantial negative gap between the unreported revenue and the significant net loss reveals a cost structure dominated by high research and development expenditures typical of clinical-stage biotechnology firms before product commercialization. Free cash flow stands at $-53,473,624, indicating that the company is burning through cash reserves to fund its operations and clinical trials rather than generating liquidity from its business activities. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which reflects the accounting treatment of costs against negligible or unreported sales revenue in the current reporting period. On the liability side, the company holds $136.85M in cash against $4.07M in debt, resulting in a debt-to-equity ratio of 5.21. Despite the high leverage ratio, the balance sheet is supported by a significant cash buffer that far exceeds total obligations. The current ratio is 2.19, signaling that the company possesses 2.19 units of current assets for every one unit of current liabilities, which suggests adequate short-term liquidity coverage. Return on Equity is -132.6% and Return on Assets is -62.3%, metrics that demonstrate the company is currently destroying shareholder value and utilizing assets to generate losses rather than profits.
Avaliação de valorização
Valuation multiples for Larimar present a mixed picture, with a trailing P/E ratio listed as N/A due to the absence of positive earnings, while the forward P/E is calculated at -2.82. The negative forward P/E implies that analysts or market models anticipate continued negative earnings in the near future, preventing the establishment of a traditional earnings-based valuation multiple. The price-to-book ratio stands at 5.41, indicating that the market values the company's equity at more than five times its book value, which suggests a significant premium based on expectations of future asset appreciation or successful drug approvals. Alternative valuation metrics such as price-to-sales and EV/EBITDA are also unavailable or negative, with EV/EBITDA at -2.30, further confirming that standard valuation frameworks based on profitability or sales efficiency do not currently apply. Regarding trading range, the 52-week high was $6.42 and the low was $1.61, providing a benchmark for price volatility and investor positioning over the last year. The company's stock price fluctuates with a beta of 1.02, which indicates that its price movements correlate closely with the broader market, exhibiting slightly higher volatility than the market average but without extreme sensitivity to general market shifts.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, reflecting the company's pre-commercialization status where historical growth rates cannot be calculated from current financial statements. Because the company does not generate positive earnings to distribute, there is no dividend yield and the payout ratio is 0.0%, meaning the company retains all available cash for reinvestment into research and development rather than distributing income to shareholders. The absence of a dividend policy is characteristic of clinical-stage biotechs, which prioritize funding their pipeline and clinical trials over returning capital to investors. Consequently, the overall growth and income profile of Larimar Therapeutics is defined entirely by its reliance on external capital markets to fund operations and its potential for future value creation through successful product development rather than current income generation or historical growth metrics.